Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma

Documenti analoghi

• The value of nasopharyngeal brush versus plasma EBV DNA detection in diagnosing local recurrence of nasopharyngeal carcinoma
  di: Yan‐Feng Ouyang, et al.
  Pubblicazione: (2026)
• FDA approves first immunotherapy drug for nasopharyngeal carcinoma
  di: Mary Beth Nierengarten
  Pubblicazione: (2024)
• Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single‐arm clinical trial
  di: Zhehao Xiao, et al.
  Pubblicazione: (2025)
• The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer
  di: Mingxiu Ju, et al.
  Pubblicazione: (2024)
• NAT10 inhibition promotes ac4C‐dependent ferroptosis to counteract sorafenib resistance in nasopharyngeal carcinoma
  di: Ziyi Xue, et al.
  Pubblicazione: (2024)